Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study.
Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Sparano JA. Solin LJ, et al. Among authors: davidson ne. Breast Cancer Res Treat. 2012 Jul;134(2):683-92. doi: 10.1007/s10549-012-2072-y. Epub 2012 May 1. Breast Cancer Res Treat. 2012. PMID: 22547108 Free PMC article.
Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.
Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, et al. Elledge RM, et al. Among authors: davidson ne. J Natl Cancer Inst. 1995 Aug 16;87(16):1254-6. doi: 10.1093/jnci/87.16.1254. J Natl Cancer Inst. 1995. PMID: 7563172 Clinical Trial. No abstract available.
A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer.
Emens LA, Kennedy MJ, Fetting JH, Davidson NE, Garrett E, Armstrong DK. Emens LA, et al. Among authors: davidson ne. Breast Cancer Res Treat. 2002 Nov;76(2):145-56. doi: 10.1023/a:1020566218512. Breast Cancer Res Treat. 2002. PMID: 12452452 Clinical Trial.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Citron ML, et al. Among authors: davidson ne. J Clin Oncol. 2003 Apr 15;21(8):1431-9. doi: 10.1200/JCO.2003.09.081. Epub 2003 Feb 13. J Clin Oncol. 2003. PMID: 12668651 Clinical Trial.
410 results